MedTrace Logo

An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer

NCT03129256 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2019-12-10

No results posted yet for this study

Summary

This study is to explore the potential efficacy and safety of low-dose Apatinib combined with S-1 in patients with advanced lung cancer. Patients with advanced NSCLC will be treated with oral apatinib and S-1 after treatment failure of standard regimen.

Conditions

Interventions

DRUG

Apatinib Mesylate tablet combined with S-1 capsules

Oral use with low-dose Apatinib combined with S-1 until disease progression

Sponsors & Collaborators

  • Changzhou Cancer Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Tong Zhou, Dr. · Changzhou Cancer Hospital of Soochow University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-01
Primary Completion
2018-12-30
Completion
2018-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03129256 on ClinicalTrials.gov